KALEIDO BIOSCIENCES INC (KLDO)

US4833471000 - Common Stock

0.29  -0.01 (-3.69%)

After market: 0.3003 +0.01 (+3.55%)

Fundamental Rating

1

Taking everything into account, KLDO scores 1 out of 10 in our fundamental rating. KLDO was compared to 198 industry peers in the Pharmaceuticals industry. KLDO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, KLDO is valued expensive at the moment.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KLDO has reported negative net income.
KLDO had negative earnings in each of the past 5 years.
KLDO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Industry RankSector Rank
ROA -180.08%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Operating Margin and Gross Margin are not available for KLDO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -8155.92%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, KLDO has more shares outstanding
Compared to 1 year ago, KLDO has a worse debt to assets ratio.

2.2 Solvency

KLDO has an Altman-Z score of -15.43. This is a bad value and indicates that KLDO is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.52 indicates that KLDO is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z -15.43
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

KLDO has a Current Ratio of 1.43. This is a normal value and indicates that KLDO is financially healthy and should not expect problems in meeting its short term obligations.
KLDO has a Quick Ratio of 1.43. This is a normal value and indicates that KLDO is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 1.43

More info and screens

4

3. Growth

3.1 Past

KLDO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.65%, which is quite good.
The Revenue has grown by 14.12% in the past year. This is quite good.
EPS 1Y (TTM)11.65%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q14.48%
Revenue 1Y (TTM)14.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q105%

3.2 Future

The Earnings Per Share is expected to grow by 0.99% on average over the next years.
Based on estimates for the next years, KLDO will show a very strong growth in Revenue. The Revenue will grow by 252.50% on average per year.
EPS Next Y10.24%
EPS Next 2Y9.33%
EPS Next 3Y4.15%
EPS Next 5Y0.99%
Revenue Next Year-36.87%
Revenue Next 2Y401.97%
Revenue Next 3Y295.27%
Revenue Next 5Y252.5%

3.3 Evolution

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KLDO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KLDO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.05

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.33%
EPS Next 3Y4.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KLDO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KALEIDO BIOSCIENCES INC

NASDAQ:KLDO (4/14/2022, 7:00:02 PM)

After market: 0.3003 +0.01 (+3.55%)

0.29

-0.01 (-3.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.36M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -180.08%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) -8155.92%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.43
Quick Ratio 1.43
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)11.65%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y10.24%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)14.12%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y